Elion Therapeutics
New York, United States· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Total funding raised: $81M
Overview
Developing next-generation small molecule antibiotics to combat drug-resistant bacterial infections.
Infectious Disease
Technology Platform
A proprietary platform for the rational design of small molecules that target essential bacterial pathways and evade common resistance mechanisms.
Funding History
1Total raised:$81M
Grant$81M
Opportunities
Significant global unmet medical need and potential for regulatory fast-track designations and pull incentives.
Risk Factors
High clinical development risk and the historically challenging economics of the antibiotic market threaten commercial viability.
Competitive Landscape
Competes with other AMR-focused biotechs like Entasis and Venatorx, as well as large pharma divisions, in a high-need but commercially difficult market.